Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

NCT07769047 on ClinicalTrials.gov · last registry update 2026-08-17

Registered but not yet open, with 50 participants planned. Due to report 30 July 2031, alongside 3 other tracked readouts that quarter. Primary outcome, as filed: Change in PWV between arms (Aim 1). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 50
Started: 2026-09-01
Primary completion: 2031-07-30 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in PWV between arms (Aim 1)

Conditions studied

Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.